<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535753</url>
  </required_header>
  <id_info>
    <org_study_id>M201791</org_study_id>
    <nct_id>NCT03535753</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of Decitabine With R-GDP</brief_title>
  <official_title>Safety and Efficacy Evaluation of Decitabine With R-GDP on Refractory or Relapsed NHL Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the Safety and efficacy of Administering decitabin plus R-GDP to NHL patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RR NHL patients will be treated with decitabin plus R-GDP , safety and efficacy will be
      assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>NHL</condition>
  <arm_group>
    <arm_group_label>Decitabine and R-GDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALL patients will be treated with Decitabine and R-GDP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine and R-GDP</intervention_name>
    <description>Decitabine and R-GDP</description>
    <arm_group_label>Decitabine and R-GDP</arm_group_label>
    <other_name>DR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed or refractory Non-Hodgkin's lymphoma(NHL) patiens.

          2. Eastern Cooperative Oncology Group(ECOG) score 0-2

          3. Expected survival &gt;3 months

          4. Measurable disease.

        Exclusion Criteria:

          1. Patients who needs treatment with immunosuppressive agents

          2. Hematosepsis or Uncontrolled active infection

          3. History of epilepsy or other CNS disease.

          4. Active hepatitis B , hepatitis C or HIV infection or any other uncontrolled active
             infection.

          5. Pregnancy or breast-feeding women.

          6. Any uncontrolled medical disorders that the researchers considered are not suitable to
             participate the clinical trial.

          7. Any situation that would increase dangerousness of subjects or disturb the outcome of
             the clinical study according to the researcher's evaluatio
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongmei Jing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xian lu, Dr</last_name>
    <phone>86</phone>
    <phone_ext>189-1157-6946</phone_ext>
    <email>luxinan@immunochina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking university third hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinan Lu, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

